Novartis Stock Slumps 1.04% Despite Robust Institutional Buys Ranks 283rd in 470M Trading Volume

Market Snapshot

On March 2, 2026, Novartis AG (NVS) closed with a 1.04% decline, underperforming broader market trends. The stock saw a trading volume of $0.47 billion, ranking 283rd in daily trading activity. Despite institutional investors such as Fisher Asset Management LLC and Loomis Sayles & Co. increasing their stakes in the second and third quarters—by 5.3% and 1.4%, respectively—short-term price momentum weakened. Institutional ownership of Novartis remains at 13.12%, reflecting mixed investor sentiment. The stock’s 50-day moving average stands at $149.91, and its 200-day average is $135.92, suggesting a potential divergence between long-term fundamentals and near-term trading dynamics.

Key Drivers

The recent pullback in Novartis’s stock price contrasts with strong institutional buying activity in late 2025. Fisher Asset Management LLC, for instance, raised its holdings by 5.3% in Q2 2025 and an additional 1.7% in Q3 2025, accumulating $928.4 million worth of shares. Similarly, Envestnet Asset Management Inc. increased its stake by 4.7% in Q3, while Country Trust Bank and Salomon & Ludwin LLC saw multi-digit percentage gains in their positions. These moves suggest confidence in Novartis’s long-term value, particularly in its pharmaceutical and healthcare innovation pipeline. However, the stock’s short-term underperformance indicates that such institutional optimism has not yet translated into broad market enthusiasm.

A notable divergence emerged in Q3 2025 as Harvest Portfolios Group Inc. trimmed its Novartis position by 1.5%, reducing its holdings to 485,330 shares valued at $62.24 million. This reduction, coupled with the stock’s 1.04% drop on March 2, highlights a tug-of-war between institutional accumulation and profit-taking by smaller investors. The firm’s stake now accounts for 1.1% of Harvest’s portfolio, marking it as the 21st-largest holding. While other major institutions like State Street Corp. and Raymond James Financial Inc. increased their stakes, the mixed institutional activity underscores uncertainty about near-term catalysts for the stock.

Novartis’s recent financial performance offers some optimism. The company exceeded quarterly earnings and revenue estimates, prompting a dividend declaration of $4.773 per share, payable March 16. Analysts maintain a “Hold” rating, with a consensus price target of $119.75. However, this target is significantly below the stock’s current price, which trades at a 23.55 price-to-earnings ratio and a 2.58 price-to-earnings-to-growth ratio. The firm’s low beta of 0.49—indicating reduced volatility relative to the broader market—suggests that macroeconomic concerns, rather than company-specific risks, may be weighing on the stock.

The broader market context also plays a role. With U.S. equities facing outflows, Novartis’s 356.17 billion market capitalization and defensive characteristics have not shielded it from cross-market pressures. Institutional investors appear focused on long-term value, but the absence of near-term earnings surprises or strategic announcements—such as major R&D breakthroughs or acquisitions—has limited upward momentum. The recent news of newcleo’s nuclear reactor contracts, while unrelated to Novartis, highlights the competitive landscape for innovation-driven healthcare and energy firms, adding context to investor caution.

In summary, Novartis’s stock faces a crosscurrent of factors: robust institutional buying, strong earnings execution, and a low-volatility profile are offset by a lack of immediate catalysts and broader market headwinds. The coming months will likely hinge on whether the company can align its long-term strategic goals with near-term investor expectations.